ArticleMedicine2025
Association between cardiovascular-kidney-metabolic health and rheumatoid arthritis prevalence: A cross-sectional study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research suggests metabolic disturbances may drive inflammation. This study explores the link between cardiovascular-kidney-metabolic syndrome (CKM) stages and rheumatoid arthritis (RA). This cross-sectional study utilized data from 8177 American adults in the 1999 to 2018 National Health and Nutrition Examination Survey. Weighted univariate and multivariate logistic regression models and subgroup analyses were applied to examine the relationship between different stages of CKM syndrome and RA prevalence. In this cross-sectional study, after adjusting for potential confounders, a higher CKM stage was found to be associated with an increased risk of RA. When compared to CKM stage 0, individuals in stages 2 (odds ratio [OR] = 2.02, 95% confidence interval [CI]: 1.06-4.25, P = .043), 3 (OR = 2.06, 95% CI: 1.03-4.73, P = .038), and 4 (OR = 2.19, 95% CI: 1.02-4.69, P = .044) showed a significantly higher risk of RA. Subgroup analysis revealed that in the 40 to 59 age group, any CKM stage above 0 was strongly linked to an increased RA risk, which was not observed in the 18 to 39 or ≥60 age groups. In females, CKM stages 2 to 4 were associated with a greater risk of RA compared to stage 0, suggesting a potential gender-related influence. Additionally, similar associations between higher CKM stages and increased RA risk were found in Other Hispanic, Non-Hispanic White, and other racial groups. This study indicates that an elevated CKM stage is significantly linked to a higher risk of RA, especially among those aged 40 to 59, females, and specific racial groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.